ESC 2020: Early Is Better for Rhythm Control in Afib
EAST-AFNET 4 findings suggest optimum treatment window is measured in months In medicine, results...
Read More
Meeting Coverage
ESC 2020: EMPEROR-Reduced Trial: Empagliflozin Reduces CV Death by 25%
Findings confirm DAPA-HF ’no fluke’ Adding empagliflozin to standard heart failure treatment...
Read More
ESC 2020: Lowering Blood Pressure Appears to Benefit Most People
Even normotensive people can reduce risks Patients with heart disease or who are at risk of...
Read More
Conference Highlights: AAIC 2020
New research was presented at AAIC 2020, the virtual Alzheimer’s Association International...
Read More
Conference Highlights: ATS 2020 Virtual
New research was presented at ATS 2020 Virtual, the online annual American Thoracic Society...
Read More
Conference Highlights: AAIC 2020
New research was presented at AAIC 2020, the virtual Alzheimer’s Association International...
Read More
ASCO 2020 Virtual Annual Meeting, Lung Cancer
[flippingbook width=”740px” height=”480px” title=”ASCO Lung Cancer...
Read More
Chemoimmunotherapy: Efficacy Among Small Cell Lung Cancer Patients
“The overall take home message from the Virtual ASCO Annual Meeting this year is that...
Read More
Conference Highlights – AIDS 2020: Virtual – A Focus on COVID-19
New research was presented at AIDS 2020: Virtual, the 23rd International AIDS Conference, from...
Read More
ASCO 2020: Atezolizumab with SABR May Be Feasible for Early State NSCLC
Phase 1 trial shows feasibility and safety of neoadjuvant and adjuvant atezolizumab with...
Read More
Phase III ADAURA Trial: Practice Changing Results for NSCLC
Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit...
Read More
New Immunotherapy Treatment Promising for NSCLC
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being...
Read More
CASPIAN Trial Update: Phase 3 Results & Perspectives
Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical...
Read MoreNivolumab and Chemo Significantly Improved Survival in ES-SCL
In the phase 2 ECOG-ACRIN EA5161 trial, a significant improvement in both progression-free and overall survival was observed from adding the checkpoint inhibitor nivolumab to chemotherapy (cisplatin/carboplatin with etoposide)...
Read More
New Second-Line Treatment Option for Malignant Pleural Mesothelioma?
To date, second-line chemotherapy is not the standard of care in patients with malignant pleural...
Read More
Conference Highlights: ADA 2020
New research was presented at ADA 2020, the virtual 80th Scientific Sessions of American Diabetes...
Read More
ASCO: Breast Cancer Brain Mets Treated with Tucatinib
Addition of agent to chemotherapy improves survival The risk of death or progression of brain...
Read More
ASCO: Larotrectinib Produces Durable Responses
TRK fusion targets multiple cancers Patients diagnosed with a variety of advanced cancers —...
Read More
ASCO: Survival Benefit Emerges in ARAMIS
Darolutamide better in non-metastatic castration-resistant prostate cancer Men diagnosed with...
Read More
ASCO: Consultant Palliation Improves AML Quality of Life
Early referral linked to better psychological outcomes Referring a patient diagnosed with acute...
Read More